Seaport Therapeutics, Inc. Common Stock
Seaport Therapeutics, Inc. Common Stock
- Market cap
- $966.23M
Your view on SPTX
Overview
What the company does, where it operates, and who runs it.
About Seaport Therapeutics, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daphne Zohar
- Headquarters
- 101 Seaport Blvd., Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daphne Zohar
- Headquarters
- 101 Seaport Blvd., Boston, MA, US
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology.
This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions.
Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications.
Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Seaport Therapeutics, Inc. Common Stock. Starting points for Seaport Therapeutics, Inc. Common Stock: EPS -$2.59, beta 1.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Seaport Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Seaport Therapeutics, Inc. Common Stock stands at -$2.59. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
2 ratings- Strong Buy0
- Buy2
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.56 | −$0.57 | −$4.13 | −$2.45 |
| Lowest estimate | −$0.66 | −$0.61 | −$4.89 | −$3.06 |
| Highest estimate | −$0.51 | −$0.54 | −$3.79 | −$2.09 |
| Number of analysts | 5 | 4 | 6 | 6 |
| A year ago | — | −$5.50 | −$1.401 | — |
| Growth vs a year ago | — | +89.7% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Lowest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Highest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Number of analysts | 0 | 0 | 0 | 0 |
| A year ago | — | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Seaport Therapeutics, Inc. Common Stock. Seaport Therapeutics, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| CTNMContineum Therapeutics, Inc. Class A Common Stock | Healthcare | Biotechnology | $306.9M | ||
| GHRSGH Research PLC | Healthcare | Biotechnology | $1.2B | ||
| KTTAPasithea Therapeutics Corp. | Healthcare | Biotechnology | $17.6M | ||
| LBRXLB Pharmaceuticals Inc Common Stock | Healthcare | Biotechnology | $1.3B | ||
| MPLTMapLight Therapeutics, Inc. | Healthcare | Biotechnology | $253.2M | ||
| NMRANeumora Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | $63.0M | ||
| QNTMQuantum BioPharma Ltd. | Healthcare | Biotechnology | $8.3M | ||
| RAPPRapport Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | $1.1B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PDSBPDS Biotechnology Corporation | Healthcare | NASDAQ | $43.4M | ||
| PEPGPepGen Inc. | Healthcare | NASDAQ | $261.8M | ||
| PFNDPathfinder Cell Therapy, Inc. | Healthcare | OTC | $66,716 | ||
| PGENPrecigen, Inc. | Healthcare | NASDAQ | $1.5B | ||
| PHARPharming Group N.V. | Healthcare | NASDAQ | $814.5M | ||
| PHATPhathom Pharmaceuticals, Inc. | Healthcare | NASDAQ | $378.8M | ||
| PHGUFPharming Group N.V. | Healthcare | OTC | $1.1B | ||
| PHIOPhio Pharmaceuticals Corp. | Healthcare | NASDAQ | $7.8M | ||
| PHMMFPharma Mar, S.A. | Healthcare | OTC | $1.5B | ||
| PHRM.CNPharmaTher Holdings Ltd. | Healthcare | CNQ | $9.1M | ||
| PHRRFPharmaTher Holdings Ltd. | Healthcare | OTC | $5.3M | ||
| PHVSPharvaris N.V. | Healthcare | NASDAQ | $2.2B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.01% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| PSILAdvisorShares Psychedelics ETF | $42M in assets | 5.43% | |
| IWCiShares Micro-Cap ETF | $1.2B in assets | 0.07% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.01% | |
| RSSLGlobal X - Russell 2000 ETF | $1.4B in assets | 0.01% | |
| IWNiShares Russell 2000 Value ETF | $13.9B in assets | 0.01% | |
Largest holders first, then the funds most concentrated in SPTX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Seaport Therapeutics, Inc. Common Stock, and how their positions are changing. At a $966.2M market value, institutional positions materially move Seaport Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Seaport Therapeutics, Inc. Common Stock executives and directors. Shares of Seaport Therapeutics, Inc. Common Stock have traded between $14.85 and $24.48 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Seaport Therapeutics, Inc. Common Stock. Coverage tracks Seaport Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Seaport Therapeutics, Inc. Common Stock.